acute myocardial infarction
Conditions
Interventions
experimental group:The standard dose of evolocumab (140mg or 420 mg) or alirocumab (75mg or 150mg) is given before PPCI
control group:The same dose of normal saline is given before PPCI
Sponsors
Southeast University Zhongda Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients with an age between 18 and 70 years old; (2) Acute myocardial infarction patients with primary percutaneous coronary intervention (PPCI) indication and consent to PPCI; (3) Patients with an ability to understand research requirements and provide informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients with a poor performance status, including coma, shock and tracheal intubation, etc; (2) Patients with severe renal insufficiency defined as estimated glomerular filtration rate (eGFR) was less than 30mL/min/1.73m2; (3) Patients with active liver disease or liver dysfunction defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) were above 3 times the upper limit of normal; (4) People with known hypersensitivity to contrast medium, heparin, aspirin, clopidogrel and ticagrelor; (5) Patients who have recently received PCSK9 inhibitors treatment; (6) Patients with with advanced cancer and have short life expectancies; (7) Pregnant or lactating women; (8) Patients with severe coronary calcification; (9) Patients unable to cooperate treatment or the researcher considers them inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| major cardiovascular adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| the change in lipid parameters; | — |
Countries
China
Contacts
Public ContactLi Yongjun
Southeast University Zhongda Hospital
Outcome results
None listed